Literature DB >> 21512636

Efficacy and Adverse Events of Platelet Transfusion Product-Specific Differences.

Peter Hellstern1.   

Abstract

SUMMARY: TWO PREPARATIONS ARE AVAILABLE FOR PLATELET TRANSFUSION: single-donor apheresis platelet concentrates (APC) and pooled platelet concentrates (PPC) prepared from 4-6 whole blood units. Clear advantages of APC over PPC are a markedly reduced donor exposure of recipients, and easier logistics when attempting a complete supply with ABO-identical and Rh-compatible platelet concentrates. Regulations should aim at complete ABO-identical platelet transfusions because major and minor ABO-incompatible platelet transfusions are probably associated with significantly increased morbidity and mortality. The main advantage of PPC is lower costs. Preparation of PPC is however inevitably accompanied by substantial wastage of plasma and red cells. Only major supraregional blood transfusion centers can guarantee full-coverage supply with ABO-identical and Rh-compatible PPC. Whether APC are more effective than PPC and associated with fewer septic platelet transfusion reactions as shown in some but not all studies, has to be examined in future prospective controlled trials.

Entities:  

Year:  2008        PMID: 21512636      PMCID: PMC3076343          DOI: 10.1159/000119117

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  44 in total

1.  ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity.

Authors:  R J Benjamin; J H Antin
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

2.  Viability of platelets collected by apheresis versus the platelet-rich plasma technique: a direct comparison.

Authors:  R A de Vries; M de Bruin; J J Marx; H C Hart; A Van de Wiel
Journal:  Transfus Sci       Date:  1993-10

3.  ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation.

Authors:  R J Benjamin; S McGurk; M S Ralston; W H Churchill; J H Antin
Journal:  Transfusion       Date:  1999-02       Impact factor: 3.157

4.  Logistics of platelet concentrates.

Authors: 
Journal:  Vox Sang       Date:  2007-02       Impact factor: 2.144

5.  Lower or higher doses for prophylactic platelet transfusions: results of a meta-analysis of randomized controlled trials.

Authors:  Joan Cid; Miguel Lozano
Journal:  Transfusion       Date:  2007-03       Impact factor: 3.157

6.  Immunologic low-responder in ABO-incompatible renal transplant recipients explored by donor-specific platelet transfusion.

Authors:  M Ishibashi; M Oshida; Y Kurata; Y Kokado; S Takahara; M Kyo; F Ikoma
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

7.  Rh-incompatible platelet transfusions--risks and consequences of sensitizing immunosuppressed patients.

Authors:  D Goldfinger; M H McGinniss
Journal:  N Engl J Med       Date:  1971-04-29       Impact factor: 91.245

8.  Association of ABO-mismatched platelet transfusions with morbidity and mortality in cardiac surgery.

Authors:  N Blumberg; J M Heal; G L Hicks; W H Risher
Journal:  Transfusion       Date:  2001-06       Impact factor: 3.157

9.  A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.

Authors:  Nancy M Heddle; Morris A Blajchman; Ralph M Meyer; Jeff H Lipton; Irwin R Walker; Graham D Sher; Lorrie A Constantini; Bruce Patterson; Robin S Roberts; Kevin E Thorpe; Mark N Levine
Journal:  Transfusion       Date:  2002-05       Impact factor: 3.157

Review 10.  The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility.

Authors:  Miguel Lozano; Joan Cid
Journal:  Transfus Med Rev       Date:  2003-01
View more
  1 in total

Review 1.  Anti-D Alloimmunization after RhD-Positive Platelet Transfusion in RhD-Negative Women under 55 Years Diagnosed with Acute Leukemia: Results of a Retrospective Study.

Authors:  Ana Villalba; Marta Santiago; Carmen Freiria; Pau Montesinos; Ines Gomez; Carolina Fuentes; Rebeca Rodriguez-Veiga; José María Fernandez; Guillermo Sanz; Miguel Angel Sanz; Nelly Carpio; Pilar Solves
Journal:  Transfus Med Hemother       Date:  2018-05-03       Impact factor: 3.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.